Mental Health, Substance Use, and Social Isolation: The Cost Drivers Nobody Measures and Every Plan Pays For

The claims data shows a member with poorly controlled diabetes. A1c above 9. Medication fills irregular. Emergency department visit for hyperglycemia. The plan sees a diabetic who is not managing their condition. The plan does not see the untreated depression that caused the member to stop taking their medication.

The claims data shows a member with three emergency department visits in six months, each for vague symptoms that do not resolve. The plan sees unexplained utilization. The plan does not see the substance use disorder generating the visits.

The claims data shows a member with chronic back pain escalating through injections toward surgery. The plan sees an MSK trajectory. The plan does not see the social isolation that amplifies pain perception, reduces engagement with conservative treatment, and accelerates progression toward surgery.

Mental health conditions, substance use disorders, and social isolation are the cost drivers that do not appear in claims coding but determine claims cost. They operate through other conditions. They amplify utilization patterns that would otherwise be routine. They are interconnected, each reinforcing the others. They are the most consequential and least measured cost categories in small group plans.

The Depression Cost Multiplier

#

Medical costs for treating patients with chronic medical conditions and comorbid mental health or substance use disorders are two to three times higher on average than the costs for patients without behavioral health comorbidities. Milliman’s 2018 analysis of integrated medical-behavioral healthcare estimated a total annual value opportunity of $179 billion in the commercial market through integration. Their earlier research documented that comorbid depression adds $411 to $721 per member per month in excess healthcare costs across chronic medical conditions, with the excess concentrated in medical spending, not behavioral health spending.

The 2020 Milliman study of 21 million commercially insured lives found that while only 27 percent had a behavioral health condition, those patients accounted for 56.5 percent of total healthcare expenditures. Among the top 10 percent of highest-cost patients, 57 percent had a mental health or substance use diagnosis. This behavioral subgroup contributed to 44 percent of all healthcare spending. Only 4.4 percent of total healthcare costs were attributed to behavioral health services. The excess cost appeared in medical and surgical claims.

The mechanism operates through adherence and engagement. Depression reduces medication adherence. A member who is depressed is less likely to fill prescriptions, take medications as directed, attend follow-up appointments, or engage with care management programs. The chronic disease that would be well-controlled with adherence becomes poorly controlled. Poorly controlled chronic disease generates emergency utilization, complications, and higher-acuity care. A Happify Health analysis of the National Health and Wellness Survey found that healthcare costs were 149 percent higher among individuals with unrecognized depression symptoms, with a Milliman study estimating that eight years of unrecognized depression adds more than $6,000 per year per person in excess healthcare costs.

The multiplier applies across chronic conditions. Depression amplifies diabetes costs. It amplifies cardiovascular disease costs. It amplifies chronic pain costs. It amplifies asthma and COPD costs. Milliman found that patients with kidney disease and comorbid depression were twice as likely to be hospitalized. The pattern is consistent: untreated depression doubles or triples the medical cost of coexisting chronic conditions, and the excess cost appears in medical claims rather than behavioral health claims.

For a small group plan, the implication is direct. The member who appears in claims data as a high-cost diabetic or high-utilization cardiovascular patient may actually be a depression patient generating excess medical claims. Treating the medical conditions without addressing the depression produces marginal improvement. Treating the depression reduces claims across all coexisting conditions. Milliman’s collaborative care research found that integrated behavioral-medical care programs reduced total healthcare costs by approximately 10 percent over four years, with savings appearing in every category of healthcare spending including pharmacy, inpatient, outpatient, and mental health specialty.

Substance Use Disorder as Cost Driver

#

The cost profile of substance use disorder in a commercially insured population operates through two channels: direct treatment costs for SUD, and medical costs for conditions caused or worsened by untreated SUD. The indirect medical channel is larger and less visible.

Direct SUD treatment includes detoxification, residential programs, intensive outpatient programs, medication-assisted treatment, and counseling. Costs range from $5,000 for outpatient treatment to $30,000 or more for residential programs. These claims appear with SUD diagnosis codes in the behavioral health benefit.

The indirect medical channel generates the larger cost burden. Emergency department utilization driven by intoxication, withdrawal, or consequences of substance use. Trauma injuries. Liver disease from alcohol. Cardiovascular complications from stimulants. Infectious disease from injection drug use. Each appears in medical claims with medical diagnosis codes. The SUD is not coded as the cause. A member with active, untreated alcohol use disorder may generate $40,000 to $80,000 in annual medical claims coded as liver disease, gastrointestinal bleeding, and trauma. The SUD diagnosis may never appear in claims data.

SAMHSA’s National Survey on Drug Use and Health indicates that approximately 10 percent of working-age adults have a substance use disorder in any given year. The commercially insured rate is somewhat lower due to employment-related selection effects, but the prevalence in level funded populations is not negligible. For a 30-person plan, two to three members statistically have SUD. The 2017 National Survey found that only 17 percent of those who needed SUD treatment received it. The remaining 83 percent generate medical claims driven by untreated substance use without any behavioral health treatment appearing in their claims history.

The Milliman high-cost patient study documented that among the highest-cost 10 percent of commercially insured patients, substance use disorders were highly prevalent and strongly correlated with elevated medical spending. Three-quarters of individuals with behavioral health diagnoses received almost no specialty behavioral treatment, despite having been diagnosed by a licensed provider. The treatment gap is the cost driver. The untreated SUD generates medical claims that no one connects to the underlying behavioral condition.

Social Isolation as Amplifier

#

Social isolation operates differently from depression and SUD. It is not a diagnosis code. It does not appear in claims data at all. Its cost is embedded entirely in the excess utilization it generates across every other condition.

The research linking social isolation to health outcomes is extensive. Julianne Holt-Lunstad’s meta-analysis in Perspectives on Psychological Science documented that the mortality risk associated with social isolation and loneliness is comparable to smoking 15 cigarettes daily. The National Academies of Sciences, Engineering, and Medicine published a comprehensive report in 2020 documenting the mechanisms: behavioral pathways (reduced medication adherence, delayed care-seeking, reduced physical activity, poor nutrition) and physiological pathways (chronic stress activation, elevated cortisol, systemic inflammation, immune suppression).

The cost impact operates through chronic disease progression and utilization intensity. A socially isolated member with diabetes is less likely to manage their condition, less likely to exercise, less likely to attend medical appointments. The diabetes progresses faster. A socially isolated member with chronic pain reports higher pain severity and uses more healthcare resources: more imaging, more injections, more specialist visits, faster progression to surgery. A socially isolated member with any chronic condition generates more emergency visits, more specialist referrals, and higher aggregate claims than a comparable member with adequate social connection.

The prevalence of social isolation has increased. The Surgeon General’s 2023 advisory on loneliness and isolation documented that approximately half of U.S. adults reported experiencing loneliness, with rates particularly elevated among younger adults and those living alone. The commercially insured working-age population is not immune. Remote work, geographic mobility, declining community attachment, and the erosion of workplace social structures affect the level funded population across demographics.

The amplification is not visible in claims data because social isolation carries no diagnosis code and no claims marker. The plan sees the resulting utilization patterns without seeing the common driver. A TPA reviewing claims for a 25-person group may observe four members with above-expected utilization across different conditions and different service categories. The pattern may share a common root in social isolation. The claims data cannot reveal it.

The Interconnection

#

These three factors belong in a single article because they form a self-reinforcing cycle that amplifies medical cost at each turn.

Social isolation increases the risk of depression. The member who lacks social connection develops depressive symptoms. Untreated depression increases the risk of substance use. The member self-medicates with alcohol or other substances. Substance use deepens social isolation. The member using substances withdraws further from relationships and community. The cycle continues, accelerating at each revolution.

The medical cost consequences compound at each stage. Depression doubles medical spending for coexisting chronic conditions. Substance use generates emergency and trauma utilization. Social isolation amplifies both. A member caught in this cycle generates medical claims three to four times the expected level for their chronic disease profile, and the claims data shows only the downstream medical consequences, not the upstream behavioral and social drivers.

Breaking the cycle at any point produces downstream medical cost reduction. Addressing depression reduces medical spending on chronic conditions by the documented 2x to 3x multiplier. Treating substance use disorder reduces emergency utilization and medical complications. Reducing social isolation improves medication adherence and care engagement across all conditions. The cost management implication, addressed in Series 10, is that effective intervention must address the interconnected system. A program that treats depression without addressing the social isolation that caused it produces temporary improvement. A program that treats SUD without addressing the depression that drives relapse produces temporary sobriety.

For small group plans, the challenge is that none of these factors appears in standard claims reporting. The plan sees downstream medical cost without seeing the upstream drivers. Intervention requires identifying at-risk members through indirect claims indicators, then providing integrated access to behavioral health services, SUD treatment, and social connection resources. The TPA that builds this identification and intervention capability across its book changes the cost trajectory for its highest-cost members. The TPA that processes claims without looking upstream watches the cycle continue.